Denizar Vianna Araújo

The Costs of Type 2 Diabetes Mellitus Outpatient Care in the Brazilian Public Health System

OBJECTIVE The prevalence of type 2 diabetes has shown a significant increase in parallel with health care costs. The objective of the Brazilian Study on Diabetes Costs (ESCUDI study) was to estimate direct and indirect costs of type 2 diabetes outpatient care in the Brazilian Public Health Care System. METHODS Data were collected from different levels of health care in eight Brazilian cities in 2007. A total of 1000 outpatients were interviewed and had their medical records data analyzed. Direct medical costs included expenses with medications, diagnostic tests, procedures, blood glucose test strips, and office visits. Nonmedical direct costs included expenses with diet products, transportation, and caregivers. Absenteeism, sick leave, and early retirement were classified as indirect costs. RESULTS Total annual cost for outpatient care was US

Estimating the cost-effectiveness of pneumococcal conjugate vaccination in Brazil

2108 per patient, out of which US

Custo-efetividade da trombólise pré-hospitalar vs intra-hospitalar no infarto agudo do miocárdio

1335 per patient of direct costs (63.3%) and US

Analysis of the cost-effectiveness of thrombolysis with alteplase in stroke.

773 per patient of indirect costs (36.7%). Costs escalated as duration of diabetes and level of health care increased. Patients with both microvascular and macrovascular complications had higher costs (US

Análise de custo-efetividade da trombólise com alteplase no Acidente Vascular Cerebral

3199 per patient) compared to those with either microvascular (US

Putting the value into biosimilar decision making: The judgment value criteria

2062 per patient) or macrovascular (US

Cost effectiveness of peginterferon alfa-2B combined with ribavirin for the treatment of chronic hepatitis C in Brazil

2517 per patient) complications only. The greatest portion of direct costs was attributed to medication (48.2%). CONCLUSIONS Diabetes treatment leads to elevated costs both to Brazilian Public Health Care System and society. Costs increased along with duration of disease, level of care and presence of chronic complications, which suggested a need to reallocate health resources focusing on primary prevention of diabetes and its complications.

Análise de custo-efetividade dos stents farmacológicos e não farmacológicos na doença coronariana

OBJECTIVE To compare the costs and benefits of pneumococcal conjugate vaccination compared with no vaccination from the perspectives of the health care system and society. METHODS Using data from established sources, we estimated the incidence and mortality due to invasive pneumococcal disease, pneumonia, and acute otitis media (AOM) for a hypothetical birth cohort of children from birth to 5 years. RESULTS A universal pneumococcal conjugate vaccination program was estimated capable of annually avoiding 1 047 cases of invasive disease, 58 226 cases of pneumonia, and 209 862 cases of AOM. When herd immunity effects were considered, the program prevented 1.3 million cases of pneumococcal disease and over 7 000 pneumococcal deaths. At a vaccination cost of R

Fraturas do fêmur proximal no idoso: estudo de custo da doença sob a perspectiva de um hospital público no Rio de Janeiro, Brasil

51.12 (US

Systematic review of pneumococcal disease costs and productivity loss studies in Latin America and the Caribbean.

26.35) per dose, vaccination would cost annually R